Direct-acting antivirals
61 articles
Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen for Chronic Hepatitis C
Results suggest a shorter treatment duration could reduce costs and improve access in low- and middle-income countries. More
Accessible DAAs Shouldn’t Be DOA: Delivering on the Promise of Negotiated Price Reductions for HCV Treatment
The hepatitis C virus remains one of the deadliest infectious diseases, despite the existence of an effective eight-to-twelve week cure. Access to direct acting antivirals must be urgently expanded to save lives. More
Immunodeficiency, Injection Drug Use Linked to Failed HCV Treatment in People with HIV
DAAs achieve a 95% success rate in treating HCV among HIV patients, but 5% experience unsuccessful treatment; Lower CD4 cell counts, HCV genotype 4, and recent injection drug use are linked to higher odds of unsuccessful treatment. More
A Cost Analysis of a Simplified Model for HCV Screening and Treatment at a Tertiary Hospital in Zimbabwe
A study designed a simplified model of HCV care and estimated the cost of screening and treatment of hepatitis C infection at a tertiary hospital in Zimbabwe. More
Clinical Outcomes and Prognostic Factors After HCV Clearance With DAA
Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. More
